A low-cost SYBR Green-based RT-qPCR method to detect SARS-CoV-2 were developed and validated. Primers targeting a conserved and vital region of the N genes of SARS-CoV-2 were designed. In-silico study was performed to analyse the compatibility of the selected primer pair with Indonesian SARS-CoV-2 genome sequences available from the GISAID database. We determined the linearity of our new assay using serial dilution of SARS-CoV-2 RNA from clinical samples with known virus concentration. The assay was then evaluated using clinically relevant samples in comparison to a commercial TaqMan-based test kit. Finally, we applied the assay in sample pooling strategies for SARS-CoV-2 detection. The SYBR Green-based RT-qPCR method was successfully developed with sufficient sensitivity. There is a very low prevalence of genome variation in the selected N primer binding regions, indicating their high conservation. The validation of the assay using clinical samples demonstrated similar performance to the TaqMan method suggesting the SYBR methods is reliable. The pooling strategy by combining 5 RNA samples for SARS-CoV-2 detection using the SYBR RT-qPCR methods is feasible and provides a high diagnostic yield. However, when dealing with samples having a very low viral load, it may increase the risk of missing positive cases.
During the COVID-19 pandemic, the standard diagnostic assay for SARS-CoV-2 detection was RT-qPCR using TaqMan probes, with samples primarily taken through nasal and oropharyngeal swabs. The TaqMan-based method is costly, highlighting the need for a more affordable alternative for SARS-CoV-2 diagnosis. As an alternative strategy, we developed and evaluated a SYBR Green-based RT-qPCR method targeting the RNA-dependent RNA polymerase (RdRp) gene of SARS-CoV-2. Under optimized RT-qPCR conditions, the sensitivity and linearity of the SYBR assays were assessed by using in vitro-transcribed RNA and RNA extracted from cultured SARS-CoV-2 isolates of the Wuhan reference strain and various circulating variants. Our results demonstrated that the SYBR Green-based RT-qPCR method was successfully developed with sufficient performance. The assay could detect up to 25 copies of in vitro-transcript RNA per reaction. Meanwhile, using the RNA extracted from cultured virus, the SYBR green assay was able to detect virus concentrations at least as low as 1 PFU/mL per reaction for all the variants tested. When tested on clinically relevant samples (88 naso-oropharyngeal swabs and 47 saliva samples), comparable results with the TaqMan assay were demonstrated. The Ct values of both methods for the positively detected samples were similar, with a difference in Ct of 0.72 ± 0.83 (p = 0.392) and −0.7765 ± 0.6107 (p = 0.209) for naso-oropharyngeal swab and saliva samples, respectively. These findings suggest that the SYBR method is reliable and thus offers an alternative assay for the detection of SARS-CoV-2. In particular, using saliva specimens could allow this assay to serve as a simple approach for SARS-CoV-2 detection.
1 January 2025 in Journal of Applied Pharmaceutical Science
Currently, mixed infections involving Candida albicans and Candida krusei have become increasingly common in cases of invasive candidiasis. Accurate identification of Candida species using polymerase chain reaction (PCR) is crucial for effective management, as timely and appropriate antifungal therapy is essential. Real-time PCR using the double-stranded DNA binding intercalating dye, offers several advantages over TaqMan chemistry, as it does not require the synthesis of specific probes, making it a more accessible option. In this study, we developed and evaluated specific primers, Ca2 and Ca3, targeting the ITS1/ITS2 regions of C. albicans and C. krusei, respectively, using intercalating dye SYBR Green chemistry. Our results demonstrate that the Ca2 primer specifically detects C. albicans, while the Ca3 primer accurately identifies C. krusei in both pure and mixed samples. Furthermore, the sensitivity of these primers remained consistent across both pure culture and blood samples, with the detection limit of the Ca2 primer pair ranging from 10 to 100 CFU/ml and the Ca3 primer pair ranging from 100 to 1,000 CFU/ml. Future work should focus on evaluating these primers in multiplex assays to further enhance their diagnostic utility.
Coronavirus disease 2019 or COVID-19 is caused by SARS-CoV-2 infection and it was first recorded in Wuhan, China, in December 2019. The gold standard method for detecting SARS-CoV-2 is TaqMan probe-based real-time polymerase chain reaction (RT-qPCR). Since this technique is expensive due to reliance on the use of fluorogenic probes, a cost-effective diagnostic test as an alternative approach for RT-qPCR diagnosis is necessary, especially in low- and middle-income countries with limited resources. In this study, we developed and validated an inexpensive SYBR Green-based RT-qPCR method to detect SARS-CoV-2. Primers targeting a conserved and vital region of the N genes of SARS-CoV-2 were designed and selected for further analysis. In-silico study was performed to analyse the compatibility of the selected primer pair with 500 Indonesian SARS-CoV-2 genome sequences available from the GISAID database, including Delta and Omicron variants. We determined the linearity of our new assay using serial dilution of SARS-CoV-2 RNA from clinical samples with known virus concentration. The assay was then evaluated using clinically relevant samples in comparison to a commercial TaqMan-based in vitro diagnostic test kit. Finally, we applied the assay in sample pooling strategies for SARS-CoV-2 detection. Our results showed that the SYBR Green-based RT-qPCR methods were sensitive and reliable as an alternative cost-effective assay for SARS-CoV-2 detection. In addition, it could be used in sample pooling strategies for mass screening testing or epidemiological surveillance purposes in the COVID-19 post-pandemic era.
BackgroundPublic health centres (PHCs) as primary healthcare in Indonesia were pivotal in handling COVID-19 detection, management, and reporting. Limited studies show various findings on COVID-19 management and its impact on further health risks, particularly in vulnerable populations like children under five years.MethodsThis cross-sectional study assessed secondary data from tracing reports, patient medical records, and integrated management childhood illness reports. Samples were collected using stratified random sampling based on three age groups (< 1 year, 1-3 years, 3-5 years) and the period of COVID-19 infection (2020, 2021, 2022) from ten district PHCs in East Jakarta. The collected data was analysed for descriptive, bivariate, and multivariate statistical analysis using IBM SPSS 26thversion.Results677 patients were included in this study, with the majority from 2021 (44.2%) with age 28 [0-60] months and male patients (52.6%). Only 4.14% of them have available records of vaccination history in PHC, so the risks of further respiratory problems based on vaccination status were not feasible to assess. 23.63% of them received the COVID-19 medications, with the most frequently prescribed vitamins-supplements (27.96%) and cough-related medications (12.17%). Patients with medications have fewer visits to PHCs in one semester after COVID-19 (U=-2,728, p=0.006). Acute upper respiratory infection was the most prevalent (30.32%) reason for patients' revisits after COVID-19 infection, and there were also reinfection cases of COVID-19 (4.52%). The risks of respiratory problems have no significant difference between age group, gender, and COVID-19 treatment history. The lack of complete and integrated data availability has become a hurdle to further analysis.ConclusionA small proportion of children under five years were receiving COVID-19 medication in PHCs and it poses a potential impact of decreasing further patient encounters with healthcare. There is a need for better health data management and integration in PHCs to be used as comprehensive assessments of community health risks, particularly for special populations.